Skip to main content
Clinical Trials/NCT06693622
NCT06693622
Recruiting
Not Applicable

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests: A Discrete Choice-Based Conjoint Analysis

University of Colorado, Denver1 site in 1 country556 target enrollmentNovember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastro Esophageal Reflux Disease
Sponsor
University of Colorado, Denver
Enrollment
556
Locations
1
Primary Endpoint
Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening tests
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decrease the number of people who die from esophageal cancer.

Detailed Description

To achieve this goal, patient preferences for BE/EAC screening tests will be evaluated through a prospective multicenter discrete choice-based conjoint survey. Patients will choose between a series of hypothetical options and rank their priorities and what they value according to differences in benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. By evaluating relative importance of test characteristics and patient prioritization the study will (1) define patient preferences and barriers for attributes of BE/EAC screening modalities to elicit the overall preferred test as well as differences in each attribute that informed that choice and (2) characterize differences in BE/EAC test preferences by patient sociodemographic characteristics (age, sex, race, ethnicity) and by the presence or absence of gastroesophageal reflux disease (GERD).

Registry
clinicaltrials.gov
Start Date
November 1, 2024
End Date
March 1, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Individual has 3 or more established risk factors for BE (age \> 50 years, chronic GERD, male, white race, smoking, obesity, family history of BE/EAC).

Exclusion Criteria

  • Unable to consent.
  • Prior diagnosis of BE/EAC.
  • Life limiting comorbidity/ disability.
  • Active dementia/ cognitive impairment.
  • Incarcerated.

Outcomes

Primary Outcomes

Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening tests

Time Frame: Baseline

A discrete choice-based conjoint analysis survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms will be used to determine the relative importance of BE/EAC screening test characteristics and patient priorities. Survey data will be reported in aggregate and factors and choices will be analyzed using the Fisher Exact and Mann-Whitney rank-sum tests. This approach will elicit the overall preferred test and differences in each test attribute that informed the patients choice.

Secondary Outcomes

  • Characterization of differences in BE/EAC test preferences by patient sociodemographic characteristics and by patient presence or absence of GERD(Baseline)

Study Sites (1)

Loading locations...

Similar Trials